[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-hypertension-oht\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-hypertension-oht":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100644992","phase-1-regn22530-for-adults-with-primary-open-angle-glaucoma-or-ocular-hypertension-100644992",false,"NCT07675824","REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension","A Phase 1\u002F2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension","BAHAMA","Key Inclusion Criteria:\n\n1. Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol\n2. Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20\u002F200) in the study eye on day 1\n3. BCVA of ≥55 EDTRS letters (Snellen equivalent of better than or equal to 20\u002F80) in the non-study eye on day 1\n4. Phakic or pseudophakic with a posterior chamber intraocular lens that has been implanted ≥3 months prior to Screening Visit 1\n5. Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality posterior segment imaging in the study eye\n\nKey Exclusion Criteria:\n\nOcular-specific exclusion criteria apply to the Study Eye only, unless otherwise specified.\n\n1. OAG or OHT secondary to pigment dispersion, pseudoexfoliation, trauma, uveitis, neovascularization, a vascular disorder, or steroid use\n2. Congenital or traumatic cataract, or visually significant cataract that is likely to require surgical intervention during the study\n3. Presence of significant corneal scarring or irregularities that could interfere with reliable IOP measurement\n4. Prior incisional or bleb-forming glaucoma surgery, suprachoroidal procedures, Trabecular Meshwork (TM)-stripping Microinvasive Glaucoma Surgery (MIGS), angle-based implants other than iStent or iridectomy\u002Firidotomy as described in the protocol\n5. History of Selective Laser Trabeculoplasty (SLT) within 6 months prior to day 1\n6. History of transscleral (including micropulse) or endoscopic cyclophotocoagulation within 1 year prior to day 1\n\nNote: Other protocol defined Inclusion\u002F Exclusion criteria apply","ALL","18 Years",{"count":20,"type":21},271,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study will test an experimental drug called REGN22530 (\"study drug\") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP).\n\nREGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure.\n\nThe study is looking at:\n\n* What side effects REGN22530 might cause\n* How much REGN22530 is in the blood and eye fluid at different times\n* If the body has any reactions to REGN22530 (which may cause REGN22530 to not work as well)\n* How the body and eye pressure respond after having REGN22530, which can help researchers understand why REGN22530 works better in some people than others\n* How well REGN22530 works",[28,29],"Primary Open Angle Glaucoma (POAG)","Ocular Hypertension (OHT)",[31,32,33],"Intraocular Pressure (IOP)","First in Human (FIH)","Open Angle Glaucoma (OAG)","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-07-23",{"date":42,"type":21},"2029-10-16",{"name":44,"class":45},"Regeneron Pharmaceuticals","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100624324","direct-vs-standard-slt-for-glaucoma-a-noninferiority-trial-100624324","NCT07408154","Direct vs Standard SLT for Glaucoma: A Noninferiority Trial","A Randomized Controlled Trial Comparing Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) in Reducing Intraocular Pressure in Open-Angle Glaucoma","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of OAG (including exfoliative or pigmentary) or OHT\n* Gonioscopically open angle (visible scleral spur 360°)\n* Ability to consent and comply with follow-up\n\nExclusion Criteria:\n\n* Angle-closure or secondary glaucomas\n* IOP \\>35 mmHg despite therapy\n* Corneal pathology interfering with laser or IOP measurement\n* Recent ocular surgery (\\\u003C6 months)\n* Contraindications to study medications or procedures\n* Cognitive impairment preventing consent",{"count":54,"type":21},172,[56],"NA","This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Participants will be randomly assigned to receive either DSLT or SLT and followed for 12 months to assess eye pressure, safety, and treatment outcomes.",[59,29],"Open-angle Glaucoma (OAG)",[61,62,63,64,65],"Glaucoma","Open-Angle Glaucoma","Ocular Hypertension","Laser Trabeculoplasty","Intraocular Pressure","RECRUITING","2026-05-04",{"date":69,"type":38},"2026-05-06",{"date":71,"type":38},"2026-04-27",{"date":73,"type":21},"2027-10",{"name":75,"class":76},"Medical University of South Carolina","OTHER",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":77},"100581333","phase-4-safety-and-efficacy-of-idose-tr-with-cataract-surgery-vs-cataract-surgery-alone-100581333","NCT06848946","Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone","Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone","Inclusion Criteria:\n\n* Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.\n* OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)\n\nExclusion Criteria:\n\n* Active corneal inflammation or edema.\n* Retinal disorders not associated with glaucoma.","45 Years",{"count":87,"type":21},132,[89],"PHASE4","This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone",[92,29,93],"Glaucoma, Open-angle","Phacoemulsification Cataract Surgery","2026-01-19",{"date":96,"type":38},"2026-01-21",{"date":98,"type":38},"2025-01-13",{"date":100,"type":21},"2027-06",{"name":102,"class":45},"Glaukos Corporation"]